[go: up one dir, main page]

DK3237406T3 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidin-2,4-dion-derivativer der anvender adamts inhibitorer til behandling af osteoarthritis - Google Patents

5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidin-2,4-dion-derivativer der anvender adamts inhibitorer til behandling af osteoarthritis Download PDF

Info

Publication number
DK3237406T3
DK3237406T3 DK15813831.3T DK15813831T DK3237406T3 DK 3237406 T3 DK3237406 T3 DK 3237406T3 DK 15813831 T DK15813831 T DK 15813831T DK 3237406 T3 DK3237406 T3 DK 3237406T3
Authority
DK
Denmark
Prior art keywords
imidazolidin
piperazin
oxo
propyl
treat osteoarthritis
Prior art date
Application number
DK15813831.3T
Other languages
English (en)
Inventor
Franck Laurent Brebion
Luke Jonathan Alvey
David Amantini
Pierre Marc Marie Joseph Deprez
Romain Luc Marie Gosmini
Helène Marie Jary
Christophe Peixoto
Marie Laurence Claire Varin
Ceuninck Frédéric André De
Iuliana Ecaterina Pop-Botez
Original Assignee
Galapagos Nv
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Servier Lab filed Critical Galapagos Nv
Application granted granted Critical
Publication of DK3237406T3 publication Critical patent/DK3237406T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15813831.3T 2014-12-22 2015-12-18 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidin-2,4-dion-derivativer der anvender adamts inhibitorer til behandling af osteoarthritis DK3237406T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14307129 2014-12-22
PCT/EP2015/080430 WO2016102347A1 (en) 2014-12-22 2015-12-18 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
DK3237406T3 true DK3237406T3 (da) 2019-05-06

Family

ID=52345014

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15813831.3T DK3237406T3 (da) 2014-12-22 2015-12-18 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidin-2,4-dion-derivativer der anvender adamts inhibitorer til behandling af osteoarthritis

Country Status (50)

Country Link
US (4) US9926281B2 (da)
EP (2) EP3237406B1 (da)
JP (2) JP6636539B2 (da)
KR (1) KR102711990B1 (da)
CN (1) CN107108579B (da)
AR (1) AR103170A1 (da)
AU (1) AU2015371400B2 (da)
BR (1) BR112017013258B1 (da)
CA (1) CA2971110C (da)
CL (1) CL2017001650A1 (da)
CO (1) CO2017006174A2 (da)
CR (1) CR20170248A (da)
CU (1) CU20170085A7 (da)
CY (1) CY1121692T1 (da)
DK (1) DK3237406T3 (da)
DO (1) DOP2017000139A (da)
EA (1) EA030637B1 (da)
EC (1) ECSP17046848A (da)
ES (1) ES2724989T3 (da)
GE (1) GEP20197043B (da)
GT (1) GT201700107A (da)
HK (1) HK1245793B (da)
HR (1) HRP20190514T1 (da)
HU (1) HUE042840T2 (da)
IL (1) IL252981B (da)
JO (1) JO3501B1 (da)
LT (1) LT3237406T (da)
MA (1) MA41238B1 (da)
MD (1) MD3237406T2 (da)
ME (1) ME03374B (da)
MX (1) MX2017008048A (da)
MY (1) MY189764A (da)
NI (1) NI201700081A (da)
NZ (1) NZ732909A (da)
PE (1) PE20171099A1 (da)
PH (1) PH12017501160A1 (da)
PL (1) PL3237406T3 (da)
PT (1) PT3237406T (da)
RS (1) RS58617B1 (da)
RU (1) RU2693459C2 (da)
SA (1) SA517381743B1 (da)
SG (1) SG11201705030SA (da)
SI (1) SI3237406T1 (da)
TN (1) TN2017000213A1 (da)
TR (1) TR201904158T4 (da)
TW (1) TWI687414B (da)
UA (1) UA122065C2 (da)
UY (1) UY36470A (da)
WO (1) WO2016102347A1 (da)
ZA (1) ZA201703905B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
GB201610055D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610056D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
CN107540648A (zh) * 2017-08-09 2018-01-05 江苏工程职业技术学院 一种达格列净的制备方法
CN107652277A (zh) * 2017-08-09 2018-02-02 江苏工程职业技术学院 一种依帕列净的制备方法
WO2021011720A2 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis compounds and related compositions and methods
EP4100005A4 (en) * 2020-02-04 2023-07-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ADAMTS INHIBITORS, METHODS OF MANUFACTURE AND MEDICAL USES THEREOF
WO2021204185A1 (zh) * 2020-04-10 2021-10-14 深圳信立泰药业股份有限公司 一种苯并[d]氮杂卓类衍生物蛋白聚糖酶2抑制剂及其制备方法和医药用途
CN113735825B (zh) * 2020-05-27 2024-08-27 成都康弘药业集团股份有限公司 1,2,3,6-四氢吡啶类化合物及其制备方法和用途
CN113754635B (zh) * 2020-06-02 2024-06-21 成都康弘药业集团股份有限公司 稠环类化合物及其制备方法和用途
CN115720578A (zh) * 2020-07-09 2023-02-28 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用
CN113943255B (zh) * 2020-07-17 2024-08-06 深圳信立泰药业股份有限公司 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法
IL303642A (en) 2020-12-15 2023-08-01 Galapagos Nv Solid forms of (5S)-cyclopropyl-5-[3-[(3S)-4-(5,3-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidin-4, 2-Dion
WO2022212638A1 (en) * 2021-04-02 2022-10-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Prodrugs of adamts inhibitors, preparation methods and medicinal uses thereof
CN117794900A (zh) * 2021-08-03 2024-03-29 江苏恒瑞医药股份有限公司 抑制adamts-5和/或adamts-4功能的化合物的晶型及其制备方法和应用
KR20240140825A (ko) 2023-03-17 2024-09-24 주식회사 셀러스 이미다졸리딘 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4680306A (en) * 1984-07-20 1987-07-14 Pfizer Inc. Sprio-imidazolones for treatment of diabetes complications
US5043447A (en) * 1987-04-24 1991-08-27 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
GB0405101D0 (en) 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
DK2650310T3 (da) 2012-04-13 2016-09-12 Rottapharm Biotech Srl Anti-ADAMTS-5-ANTISTOF, derivater og anvendelser deraf
AR092971A1 (es) * 2012-10-26 2015-05-06 Lilly Co Eli Inhibidores de agrecanasa
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
JO3501B1 (ar) * 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)

Also Published As

Publication number Publication date
HUE042840T2 (hu) 2019-07-29
CA2971110A1 (en) 2016-06-30
CL2017001650A1 (es) 2018-01-26
DOP2017000139A (es) 2017-10-31
AR103170A1 (es) 2017-04-19
BR112017013258A8 (pt) 2022-08-16
PE20171099A1 (es) 2017-08-07
MX2017008048A (es) 2017-10-19
US10941117B2 (en) 2021-03-09
US20210309614A1 (en) 2021-10-07
SI3237406T1 (sl) 2019-04-30
IL252981B (en) 2019-07-31
RU2017126187A3 (da) 2019-01-24
BR112017013258A2 (pt) 2018-02-06
RU2693459C2 (ru) 2019-07-03
GEP20197043B (en) 2019-11-25
MA41238B1 (fr) 2019-04-30
PL3237406T3 (pl) 2019-07-31
SG11201705030SA (en) 2017-07-28
US20200216397A1 (en) 2020-07-09
TW201629041A (zh) 2016-08-16
WO2016102347A1 (en) 2016-06-30
SA517381743B1 (ar) 2021-01-28
CA2971110C (en) 2023-05-16
EP3237406B1 (en) 2019-02-06
HRP20190514T1 (hr) 2019-05-03
GT201700107A (es) 2019-08-07
EA201791451A1 (ru) 2017-11-30
IL252981A0 (en) 2017-08-31
US20180002293A1 (en) 2018-01-04
US11718588B2 (en) 2023-08-08
CY1121692T1 (el) 2020-07-31
PH12017501160A1 (en) 2017-12-11
RS58617B1 (sr) 2019-05-31
KR20170122720A (ko) 2017-11-06
TWI687414B (zh) 2020-03-11
CN107108579A (zh) 2017-08-29
BR112017013258B1 (pt) 2023-02-07
EP3575294A1 (en) 2019-12-04
MA41238A (fr) 2017-11-01
ES2724989T3 (es) 2019-09-18
TN2017000213A1 (en) 2018-10-19
JP2020063278A (ja) 2020-04-23
CR20170248A (es) 2017-07-19
CN107108579B (zh) 2019-12-17
MY189764A (en) 2022-03-03
KR102711990B1 (ko) 2024-10-02
RU2017126187A (ru) 2019-01-24
JO3501B1 (ar) 2020-07-05
CO2017006174A2 (es) 2017-09-11
NI201700081A (es) 2017-09-08
UA122065C2 (uk) 2020-09-10
PT3237406T (pt) 2019-03-19
ZA201703905B (en) 2022-03-30
JP6636539B2 (ja) 2020-01-29
ME03374B (me) 2020-01-20
MD3237406T2 (ro) 2019-05-31
UY36470A (es) 2016-07-29
AU2015371400A1 (en) 2017-07-06
JP2018502906A (ja) 2018-02-01
EP3237406A1 (en) 2017-11-01
NZ732909A (en) 2020-08-28
US20180258052A1 (en) 2018-09-13
TR201904158T4 (tr) 2019-05-21
US9926281B2 (en) 2018-03-27
AU2015371400B2 (en) 2019-07-25
EA030637B1 (ru) 2018-09-28
LT3237406T (lt) 2019-03-25
HK1245793B (zh) 2020-01-03
US10487060B2 (en) 2019-11-26
ECSP17046848A (es) 2017-10-31
CU20170085A7 (es) 2017-10-05

Similar Documents

Publication Publication Date Title
DK3237406T3 (da) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidin-2,4-dion-derivativer der anvender adamts inhibitorer til behandling af osteoarthritis
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3371171T3 (da) Inhibitorer af RET
LT3377488T (lt) Heterocikliniai junginiai, kaip imunomoduliatoriai
DK3390395T3 (da) Forbindelser, der kan anvendes som kinase-inhibitorer
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
CL2016002502A1 (es) Inhibidores de biaril cinasa
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
ES2716415T3 (es) Espirocicloheptanos como inhibidores de ROCK
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
DK3164130T3 (da) Heteroaryle forbindelser anvendelige som inhibatorer af sumo-aktiverende enzym
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3235819T3 (da) Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
LT3288944T (lt) Imidazopirazinonai, kaip pde1 inhibitoriai
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
LT3371165T (lt) Btk inhibitorius, naudojamas vėžiui gydyti
DK3341379T3 (da) EZH2-hæmmere